What is Vivesto?
Vivesto AB operates as a specialized pharmaceutical entity dedicated to the research and development of novel therapeutic interventions. The company distinguishes itself through a proprietary drug delivery technology platform designed to enhance the solubility, safety, and overall efficacy of oncology treatments. Its current portfolio includes the commercialized asset Apealea, developed in collaboration with Elevar Therapeutics, alongside a robust pipeline featuring Cantrixil and docetaxel micellar. These assets target advanced stages of ovarian and prostate cancer, positioning Vivesto as a critical player in the precision medicine landscape. By focusing on high-barrier-to-entry oncology segments, the firm maintains a competitive edge in the biotechnology sector, bridging the gap between laboratory innovation and clinical application.
How much funding has Vivesto raised?
Vivesto has raised a total of $31.2M across 4 funding rounds:
Stock Offering
$9.5M
Debt
$3.4M
Debt
$5.2M
Debt
$13.1M
Stock Issuance/Offering (2015): $9.5M, investors not publicly disclosed
Debt (2016): $3.4M, investors not publicly disclosed
Debt (2016): $5.2M, investors not publicly disclosed
Debt (2018): $13.1M, investors not publicly disclosed
Key Investors in Vivesto
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Vivesto?
With the recent influx of capital, Vivesto is expected to prioritize the advancement of its clinical-stage pipeline, specifically focusing on the regulatory milestones for its micellar-based drug candidates. The strategic roadmap likely involves expanding the reach of its proprietary technology to address broader oncology indications, thereby diversifying its therapeutic footprint. As the company transitions into a more mature phase of enterprise-level operations, stakeholders will be monitoring the progression of Cantrixil and docetaxel micellar through late-stage clinical trials. Future growth will be contingent upon the successful execution of these development programs and the potential for further strategic partnerships to scale the commercialization of its existing and future assets in the global pharmaceutical market.
See full Vivesto company page
